An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

[1]  F. Scolari,et al.  Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience , 2020, American Journal of Transplantation.

[2]  N. Sumrani,et al.  COVID‐19 pneumonia in kidney transplant recipients: Focus on immunosuppression management , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  M. Betjes,et al.  COVID‐19 in solid organ transplant recipients: a single‐center experience , 2020, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  U. Maggiore,et al.  How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  Sumit Mohan,et al.  Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[6]  J. Qu,et al.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.

[7]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[8]  S. Bae,et al.  Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19 , 2020, Clinical Microbiology and Infection.

[9]  K. Davidson,et al.  COVID-19 in kidney transplant recipients , 2020, American Journal of Transplantation.

[10]  E. Akalin,et al.  Covid-19 and Kidney Transplantation , 2020, The New England journal of medicine.

[11]  N. Uriel,et al.  COVID-19 in solid organ transplant recipients: Initial report from the US epicenter , 2020, American Journal of Transplantation.

[12]  S. Mohan.  Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York. , 2020, Journal of the American Society of Nephrology : JASN.

[13]  S. McAdoo,et al.  COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm? , 2020, Journal of the American Society of Nephrology : JASN.

[14]  Bin Liu,et al.  Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China , 2020, European Urology.

[15]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[16]  A. Gasbarrini,et al.  Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection , 2020, Journal of medical virology.

[17]  J. Aguado,et al.  COVID-19 in solid organ transplant recipients: A single-center case series from Spain , 2020, American Journal of Transplantation.

[18]  Binqing Fu,et al.  Why tocilizumab could be an effective treatment for severe COVID-19? , 2020, Journal of Translational Medicine.

[19]  J. Qu,et al.  Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial , 2020, medRxiv.

[20]  W. Zhou,et al.  Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients , 2020, American Journal of Transplantation.

[21]  Sapna Shah,et al.  COVID-19 infection in kidney transplant recipients , 2020, Kidney International.

[22]  F. Scolari,et al.  A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia , 2020, Kidney International.

[23]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[24]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[25]  U. Maggiore,et al.  COVID-19 in kidney transplant recipients , 2020, American Journal of Transplantation.

[26]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[27]  F. Diekmann,et al.  Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? , 2020, American Journal of Transplantation.

[28]  Sharukh Lokhandwala,et al.  Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.

[29]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[30]  Yu Shi,et al.  Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan , 2020, Critical Care.

[31]  Hanxiong Guan,et al.  Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression , 2020, American Journal of Transplantation.

[32]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[33]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[34]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[35]  A. Gaber,et al.  Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center , 2020, Transplantation.

[36]  A. von Brunn,et al.  Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 , 2012, Virus Research.

[37]  M. V. van Hemert,et al.  Cyclosporin A inhibits the replication of diverse coronaviruses. , 2011, The Journal of general virology.